Table 2 Safety profiles
From: Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials
|  | n = 21 | Percent |
|---|---|---|
Dose-limiting toxicity (DLT) | 0 | 0 |
Severe adverse events (SAE) | 1 | 4.8 |
 Death (due to progressive disease) | 1 | 4.8 |
Grade 3 or higher toxicity | 2 | 9.5 |
 Blood system disorders | 1 | 4.8 |
 Laboratory abnormalities | 1 | 4.8 |